Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers
Open Access
- 23 June 2020
- journal article
- research article
- Published by Springer Nature in Translational Neurodegeneration
- Vol. 9 (1) , 1-13
Abstract
Background: The clinical presentations of frontotemporal dementia (FTD) are diverse and overlap with other neurological disorders. There are, as of today, no biomarkers in clinical practice for diagnosing the disorders. Here, we aimed to find protein markers in cerebrospinal fluid (CSF) from patients with FTD, presymptomatic mutation carriers and non-carriers.Methods: Antibody suspension bead arrays were used to analyse 328 proteins in CSF from patients with behavioural variant FTD (bvFTD,n = 16) and progressive primary aphasia (PPA,n = 13), as well as presymptomatic mutation carriers (PMC,n = 16) and non-carriers (NC,n = 8). A total of 492 antibodies were used to measure protein levels by direct labelling of the CSF samples. The findings were further examined in an independent cohort including 13 FTD patients, 79 patients with Alzheimer’s disease and 18 healthy controls.Results: We found significantly altered protein levels in CSF from FTD patients compared to unaffected individuals (PMC and NC) for 26 proteins. The analysis show patterns of separation between unaffected individuals and FTD patients, especially for those with a clinical diagnosis of bvFTD. The most statistically significant differences in protein levels were found for VGF, TN-R, NPTXR, TMEM132D, PDYN and NF-M. Patients with FTD were found to have higher levels of TN-R and NF-M, and lower levels of VGF, NPTXR, TMEM132D and PDYN, compared to unaffected individuals. The main findings were reproduced in the independent cohort.Conclusion: In this pilot study, we show a separation of FTD patients from unaffected individuals based on protein levels in CSF. Further investigation is required to explore the CSF profiles in larger cohorts, but the results presented here has the potential to enable future clinical utilization of these potential biomarkers within FTD.Keywords
Funding Information
- schörling family foundation
- KTH Center for Applied Precision Medicine
- Erling-Perssons Stiftelse
- JPND Prefrontals Swedish Research Council (529-2014-7504)
- Swedish Research Council (2015-02926, 2018-02754)
- Swedish brain foundation
- swedish alzheimer foundation
- Stockholm County Council ALF
- Karolinska Institutet Doctoral Funding
- StratNeuro, Swedish Demensfonden
- Knut och Alice Wallenbergs Stiftelse
This publication has 65 references indexed in Scilit:
- Brain site-specific proteome changes in aging-related dementiaExperimental & Molecular Medicine, 2013
- A Pan‐European Study of theC9orf72Repeat Associated withFTLD: Geographic Prevalence, Genomic Instability, and Intermediate RepeatsHuman Mutation, 2012
- Replication and meta-analysis of TMEM132D gene variants in panic disorderTranslational Psychiatry, 2012
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Age-Dependent Changes in the Cerebrospinal Fluid Proteome by Slow Off-Rate Modified Aptamer ArrayThe American Journal of Pathology, 2012
- Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALSNeuron, 2011
- A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTDNeuron, 2011
- Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementiaBrain, 2011
- Novel CSF biomarkers for frontotemporal lobar degenerationsNeurology, 2010
- 30 years of dynorphins — New insights on their functions in neuropsychiatric diseasesPharmacology & Therapeutics, 2009